HilleVax, Inc. (NASDAQ:HLVX) Receives Consensus Rating of “Hold” from Analysts

HilleVax, Inc. (NASDAQ:HLVX) has earned an average rating of “Hold” from the six research firms that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold rating. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $9.20.

A number of analysts recently commented on HLVX shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $5.00 price objective (down previously from $24.00) on shares of HilleVax in a research note on Monday, July 8th. Leerink Partners downgraded shares of HilleVax from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $28.00 to $2.00 in a report on Tuesday, July 9th. Guggenheim lowered shares of HilleVax from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. HC Wainwright restated a “neutral” rating and set a $2.00 target price on shares of HilleVax in a research report on Monday, August 12th. Finally, Stifel Nicolaus downgraded HilleVax from a “buy” rating to a “hold” rating and cut their price target for the company from $34.00 to $3.00 in a report on Tuesday, July 9th.

Hedge Funds Weigh In On HilleVax

A number of large investors have recently bought and sold shares of HLVX. abrdn plc purchased a new position in shares of HilleVax in the 4th quarter worth about $433,000. Swiss National Bank increased its position in HilleVax by 22.4% during the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after purchasing an additional 7,000 shares in the last quarter. Franklin Resources Inc. raised its holdings in HilleVax by 4.1% in the fourth quarter. Franklin Resources Inc. now owns 1,846,396 shares of the company’s stock valued at $29,635,000 after buying an additional 71,938 shares during the period. Catalys Pacific LLC acquired a new position in HilleVax during the fourth quarter valued at approximately $21,009,000. Finally, EntryPoint Capital LLC purchased a new stake in HilleVax during the first quarter worth approximately $80,000. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Trading Down 1.1 %

Shares of HLVX opened at $1.87 on Thursday. HilleVax has a 12-month low of $1.55 and a 12-month high of $20.22. The stock has a market cap of $92.98 million, a P/E ratio of -0.57 and a beta of 0.80. The company has a 50-day moving average of $3.97 and a two-hundred day moving average of $11.03.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). As a group, analysts forecast that HilleVax will post -2.47 EPS for the current fiscal year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.